ASCO Urges Expansion of Cancer Research to Include More Older Adults

ASCO Urges Expansion of Cancer Research to Include More Older Adults

 It is about damn time. The silver tsunami is hitting us and cancer incidence is proportional to age. Since inception most trials limited enrollment of what they thought were the elderly and had overly restrictive clinical trial eligibility that impedes evidence base for treating older adults with cancer How in the hell are we going to help those over 60 where over 60% of cancers occurs if we do not allow entrance in trials of much older folks DR RYAN

ASCO  issued landmark recommendations calling for federal agencies and the cancer research community to broaden clinical trials to include older adults. ASCO also called for redefining eligibility for clinical trials. Both calls to action were published in the Journal of Clinical Oncology.

More than 60 percent of cancers in the United States occur in people age 65 and older, a population that will grow exponentially over the coming years. Yet, the evidence base for treating older adults is sparse because they are underrepresented in clinical trials and trials designed specifically for them are rare.

“Older people living with cancer often have different experiences and outcomes in their treatment than younger cancer patients,” said ASCO President Julie M. Vose, MD, MBA, FASCO.  “As we age, for example, the risk of adverse reactions from treatment significantly increases. Older adults must be involved in clinical trials so we can learn the best way to treat older cancer patients resulting in improved outcomes and manageable toxicity.”

Developed by ASCO’s Cancer Research Committee, the ASCO position statement, “Improving the Evidence Base for Treating Older Adults with Cancer,” makes the five following over-arching recommendations:

•    Use clinical trials to improve the evidence base for treating older adults.
•    Leverage research designs and infrastructure to improve the evidence base for treating older adults.
•    Increase Food and Drug Administration (FDA) authority to incentivize and require research on older adults with cancer.
•    Increase clinicians’ recruitment of older adults with cancer into clinical trials.
•    Utilize journal policies to incentivize researchers to consistently report on the age distribution and health risk profiles of research participants.

ASCO also details 16 specific action steps to implement its recommendations, including asking regulatory agencies, research funders, and researchers to carefully consider whether evidence exists to support eligibility criteria based on age, performance status, or comorbid conditions—three primary reasons older adults are excluded from clinical trials.

Furthermore, ASCO encourages researchers to adopt innovative trial designs that would fill knowledge gaps in the treatment of older adults with cancer.

“We need to see clinical trials that mirror the age distribution and health risk profile of patients with cancer,” said Arti Hurria, MD, Director of City of Hope’s Cancer and Aging Research Program and co-author of the ASCO position statement. “ASCO has laid out a multi-pronged approach to expand the participation of older adults in clinical trials, ensuring that all patients will receive high-quality, evidence-based cancer care.”

Redefining Eligibility Criteria for Clinical Trials

In a related effort, ASCO’s Cancer Research Committee released a paper, “Modernizing Eligibility Criteria for Molecularly Driven Trials,” which examines the need to redefine eligibility criteria around the specific population being researched especially as molecular medicine advances.

“Understanding the risks and benefits of a treatment in the intended patient population is the fundamental goal of clinical trials,” said Edward Kim, MD, Chair of Solid Tumor Oncology and Investigational Therapeutics at Carolinas HealthCare System’s Levine Cancer Institute and Immediate Past Chair of the ASCO Cancer Research Committee. “Enrollment into clinical trials has not been optimal and needs urgent reassessment. The era of molecularly-targeted therapy is an exciting one and requires us to reevaluate how we meet this primary objective in order to expedite approval of promising drugs into the clinic.”

Next Steps

To advance the issues raised in its position statement and paper, ASCO plans to organize a public meeting with input from regulatory bodies and key stakeholders with the ultimate goal of developing an algorithmic approach to determining eligibility criteria for individual study protocols which may help guide future investigators in the era of molecularly-driven therapy. The meeting will be held in the Fall of 2016.

To read both statements, please click on the titles below:

For more information please contact Apoorva Stull at or 571-483-1355.

Advocacy Category:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s